Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HuM195 in AML Patients Failing Standard Treatment in Study 195-301
NCT00006084Phase 2Unknown
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Feb 2001
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of lintuzumab in acute myeloid leukemia (AML), sponsored by UCLA Jonsson Comprehensive Cancer Center. Status: unknown.
02
Drugs
lintuzumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00006084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006084.